MedPlus Health Services Subsidiary Faces Drug License Suspension in Karnataka
MedPlus Health Services Limited disclosed that its subsidiary Optival Health Solutions Private Limited received a drug license suspension order for a store in Ganeshpeth Hubli, Karnataka. The three-day suspension was issued by the Assistant Director, Drugs Control Administration for violations under Rule 65 of Drugs and Cosmetics Act, 1940, with a quantified potential revenue loss of Rs 0.97 lacs.
*this image is generated using AI for illustrative purposes only.
MedPlus Health Services Limited has disclosed that its subsidiary Optival Health Solutions Private Limited received a suspension order for a drug license of a store located in Karnataka, according to a regulatory filing submitted on May 1, 2026. The company made this disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Karnataka Drug License Suspension Details
The suspension order was issued by the Assistant Director, Drugs Control Administration, Hubli Circle, Hubli, Karnataka, and was received on April 30, 2026. The action pertains to a store situated at Ganeshpeth Hubli, Karnataka.
| Parameter | Details |
|---|---|
| Authority | Assistant Director, Drugs Control Administration, Hubli Circle |
| Location | Ganeshpeth Hubli, Karnataka |
| Nature of Action | Suspension of Drug License for three days |
| Date of Order Receipt | April 30, 2026 |
| Violation | Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945 |
| Potential Revenue Loss | Rs 0.97 lacs |
Regulatory Compliance Framework
The disclosure was made pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. The company has provided detailed information about the nature of violations and their financial impact as required under the regulatory framework.
Corporate Communication and Transparency
The regulatory filing was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer, and submitted to both BSE Limited and National Stock Exchange of India Limited. The company has made the documentation available on its official website at www.medplusindia.com , as well as on the stock exchange websites www.bseindia.com and www.nseindia.com .
| Exchange | Details |
|---|---|
| BSE Scrip Code | 543427 |
| NSE Symbol | MEDPLUS |
| Filing Date | May 1, 2026 |
| Compliance Officer | Manoj Kumar Srivastava |
The company continues to maintain transparency in its regulatory communications and has quantified the potential financial impact of the suspension order at Rs 0.97 lacs in terms of revenue loss during the three-day suspension period.
Historical Stock Returns for Medplus Health Services
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.73% | +7.23% | +9.67% | +22.08% | +8.87% | -14.92% |
Will this regulatory action trigger increased scrutiny from Karnataka's drug control authorities across MedPlus's other stores in the state?
How might this compliance violation impact MedPlus's expansion plans in Karnataka and other southern Indian markets?
Could this incident affect MedPlus's relationships with pharmaceutical suppliers or impact their ability to secure new drug distribution partnerships?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
